Outcomes of cancer patients treated with drotrecogin alfa (activated) for severe sepsis.

被引：0
|
作者：
Joyce, D [1 ]
Leclerc, J [1 ]
Nelson, D [1 ]
Levy, H [1 ]
Garg, R [1 ]
机构：
[1] Lilly Res Labs, Indianapolis, IN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6055
引用
收藏
页码：532S / 532S
页数：1
相关论文
共 50 条
  • [1] Drotrecogin alfa: Underutilized in severe sepsis.
    Kapoor, Pooja
    Trottier, Steven J.
    Brien, Jacklyn O.
    Veremakis, Christopher
    [J]. CRITICAL CARE MEDICINE, 2006, 34 (12) : A109 - A109
  • [2] Management of patients with severe sepsis, treated by drotrecogin alfa (activated)
    Laterre, PF
    Heiselman, D
    [J]. AMERICAN JOURNAL OF SURGERY, 2002, 184 (6A): : 39S - 46S
  • [3] Drotrecogin alfa (activated): implementing institutional guidelines for use and assessing treatment outcomes in patients with severe sepsis.
    Clarke, H
    Barlows, TG
    Machado, C
    Dalin, G
    Prager, R
    [J]. PHARMACOTHERAPY, 2002, 22 (10): : 1374 - 1375
  • [4] Patterns of survival in patients with severe sepsis treated with drotrecogin alfa (activated)
    Williams, MD
    Macias, W
    Nelson, D
    [J]. CHEST, 2004, 126 (04) : 723S - 723S
  • [5] Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated)
    Levi, Marcel
    Levy, Mitchell
    Williams, Mark D.
    Douglas, Ivor
    Artigas, Antonio
    Antonelli, Massimo
    Wyncoll, Duncan
    Janes, Jonathan
    Booth, Frank V.
    Wang, Dazhe
    Sundin, David P.
    Macias, William L.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 176 (05) : 483 - 490
  • [6] Drotrecogin alfa (activated) in severe sepsis
    Baillie, JK
    Murray, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01): : 95 - 95
  • [7] Drotrecogin alfa (activated) in severe sepsis
    Janes, Jonathan M.
    Vangerow, Burkhard
    Costigan, Timothy M.
    Macias, William L.
    [J]. LANCET INFECTIOUS DISEASES, 2013, 13 (02): : 108 - 109
  • [8] Identifying patients with severe sepsis who should not be treated with drotrecogin alfa (activated)
    Morris, PE
    Light, RB
    Garber, GE
    [J]. AMERICAN JOURNAL OF SURGERY, 2002, 184 (6A): : 19S - 24S
  • [9] Predictors of hospital mortality for patients with severe sepsis treated with drotrecogin alfa (activated)
    Micek, ST
    Isakow, W
    Shannon, W
    Kollef, MH
    [J]. PHARMACOTHERAPY, 2005, 25 (01): : 26 - 34
  • [10] Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
    Howard Levy
    Pierre-Francois Laterre
    Becky Bates
    Rebecca L Qualy
    [J]. Critical Care, 9
12345